

117TH CONGRESS
2D SESSION

H. R. 7051

To amend titles XVIII and XIX of the Social Security Act to provide for coverage of prescription digital therapeutics under such titles, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 9, 2022

Mr. THOMPSON of California (for himself and Mr. MCKINLEY) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend titles XVIII and XIX of the Social Security Act to provide for coverage of prescription digital therapeutics under such titles, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Access to Prescription
5 Digital Therapeutics Act of 2022”.

1 **SEC. 2. COVERAGE AND PAYMENT OF PRESCRIPTION DIG-**
2 **ITAL THERAPEUTICS UNDER THE MEDICARE**
3 **PROGRAM.**

4 (a) PRESCRIPTION DIGITAL THERAPEUTIC DE-
5 FINED.—Section 1861 of the Social Security Act (42
6 U.S.C. 1395x) is amended by adding at the end the fol-
7 lowing new subsection:

8 “(III) PRESCRIPTION DIGITAL THERAPEUTIC.—The
9 term ‘prescription digital therapeutic’ means a product,
10 device, internet application, or other technology that—

11 “(1) is cleared or approved under section
12 510(k), 513(f)(2), or 515 of the Federal Food,
13 Drug, and Cosmetic Act;

14 “(2) has a cleared or approved indication for
15 the prevention, management, or treatment of a med-
16 ical disease, condition, or disorder;

17 “(3) primarily uses software to achieve its in-
18 tended result; and

19 “(4) is a device that is exempt from section
20 502(f)(1) of the Federal Food, Drug, and Cosmetic
21 Act under section 801.109 of title 21 of the Code of
22 Federal Regulations (or any successor regulation).”.

23 (b) COVERAGE AS MEDICAL AND OTHER HEALTH
24 SERVICE.—Section 1861(s)(2) of the Social Security Act
25 (42 U.S.C. 1395x(s)(2)) is amended—

1 (1) in subparagraph (GG), by striking “and” at
2 the end;

3 (2) in subparagraph (HH), by striking the pe-
4 riod at the end and inserting “; and”; and

5 (3) by adding at the end the following new sub-
6 paragraph:

7 “(II) prescription digital therapeutics fur-
8 nished on or after January 1, 2023;”.

9 (c) **REQUIREMENTS FOR PRESCRIPTION DIGITAL**
10 **THERAPEUTICS UNDER MEDICARE.**—Part B of the Social
11 Security Act (42 U.S.C. 1395j et seq.) is amended by in-
12 serting after section 1834A the following new section:

13 **“SEC. 1834B. REQUIREMENTS FOR PRESCRIPTION DIGITAL**
14 **THERAPEUTICS.**

15 “(a) **PAYMENT.**—

16 “(1) **IN GENERAL.**—Not later than 1 year after
17 the date of enactment of this section, the Secretary
18 shall establish a payment methodology for manufac-
19 turers of prescription digital therapeutics, which
20 may consist of a one-time payment or periodic pay-
21 ments, as determined appropriate by the Secretary.

22 “(2) **CONSIDERATIONS FOR PAYMENT METHODOD-**
23 **LOGY.**—For purposes of establishing the payment
24 methodology under paragraph (1), the Secretary
25 shall consider—

1 “(A) the actual list charge of such pre-
2 scription digital therapeutic;

3 “(B) the weighted median (calculated by
4 arraying the distribution of all payment rates
5 reported for the most recent period for which
6 such rates were reported under subsection
7 (c)(1) for each prescription digital therapeutic
8 weighted by volume for each payor and each
9 manufacturer) for such prescription digital
10 therapeutic;

11 “(C) in the case of a prescription digital
12 therapeutic that requires ongoing use, the
13 amount for such ongoing use; and

14 “(D) other factors as determined by the
15 Secretary.

16 “(b) CODING.—

17 “(1) IN GENERAL.—Not later than 2 years
18 after the date of enactment of this section, the Sec-
19 retary shall establish product-specific HCPCS codes
20 for prescription digital therapeutic covered under
21 this title.

22 “(2) TEMPORARY CODE.—The Secretary shall
23 adopt temporary product-specific HCPCS codes for
24 purposes of providing payment under this title until

1 a permanent product-specific HCPCS code has been
2 established under paragraph (1).

3 “(c) MANUFACTURER REPORTING.—

4 “(1) IN GENERAL.—Beginning on January 1,
5 2023, each manufacturer of a prescription digital
6 therapeutic covered under this title shall submit to
7 the Secretary, at such time and in such manner as
8 specified by the Secretary, and annually thereafter,
9 a report describing—

10 “(A) the payment rate that was paid by
11 each private payor for each prescription digital
12 therapeutic during the period specified by the
13 Secretary;

14 “(B) the volume of such prescription dig-
15 ital therapeutic distributed to each such payor
16 for such period; and

17 “(C) the number of individual users of
18 such prescription digital therapeutic for such
19 period.

20 “(2) TREATMENT OF DISCOUNTS.—The pay-
21 ment rate reported by a manufacturer in accordance
22 with paragraph (1)(A) shall reflect all discounts, re-
23 bates, coupons, and other price concessions, includ-
24 ing those described in section 1847A(c)(3).

25 “(3) CIVIL MONETARY PENALTY.—

1 “(A) IN GENERAL.—If the Secretary deter-
2 mines that a manufacturer has failed to report,
3 or made a misrepresentation or omission in re-
4 porting, information under this subsection with
5 respect to a prescription digital therapeutic, the
6 Secretary may apply a civil money penalty in an
7 amount of up to \$10,000 per day for each fail-
8 ure to report or each such misrepresentation or
9 omission.

10 “(B) APPLICATION.—The provisions of
11 section 1128A (other than subsections (a) and
12 (b)) shall apply to a civil money penalty under
13 this paragraph in the same manner as they
14 apply to a civil money penalty or proceeding
15 under section 1128A(a).

16 “(4) CONFIDENTIALITY.—Information reported
17 under this subsection shall be treated in the same
18 manner in which information is disclosed by a manu-
19 facturer or a wholesaler of a covered outpatient is
20 treated under section 1927(b)(3)(D).

21 “(d) DEFINITIONS.—For purposes of this section:

22 “(1) ACTUAL LIST CHARGE.—The term ‘actual
23 list charge’ means the publicly available payment
24 rate for a prescription digital therapeutic on the first

1 day that such prescription digital therapeutic is
2 available for purchase by a private payor.

3 “(2) HCPCS.—The term ‘HCPCS’ means, with
4 respect to an item, the code under the Healthcare
5 Common Procedure Coding System (HCPCS) (or a
6 successor code) for such item.

7 “(3) MANUFACTURER.—The term ‘manufac-
8 turer’ has the meaning given such term by section
9 820.3(o) of title 21, Code of Federal Regulations (or
10 any successor regulation).

11 “(4) PRESCRIPTION DIGITAL THERAPEUTIC.—
12 The term ‘prescription digital therapeutic’ has the
13 meaning given such term in section 1861(lll).

14 “(5) PRIVATE PAYOR.—The term ‘private
15 payor’ has the meaning given such term in section
16 1834A(a)(8).”

17 **SEC. 3. COVERAGE OF PRESCRIPTION DIGITAL THERA-**
18 **PEUTICS UNDER THE MEDICAID PROGRAM.**

19 Section 1905(a) of the Social Security Act (42 U.S.C.
20 1396d(a)) is amended—

21 (1) in paragraph (30), by striking “; and” and
22 inserting a semicolon;

23 (2) by redesignating paragraph (31) as para-
24 graph (32); and

1 (3) by inserting the following paragraph after
2 paragraph (30):

3 “(31) prescription digital therapeutics (as de-
4 fined in section 1861(III)); and”.

○